| Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function A Viale, P Pettazzoni, CA Lyssiotis, H Ying, N Sánchez, M Marchesini, ... Nature 514 (7524), 628-632, 2014 | 1226 | 2014 |
| ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma M Marchesini, Y Ogoti, E Fiorini, AA Samur, L Nezi, M D'Anca, P Storti, ... Cancer cell 32 (1), 88-100. e6, 2017 | 142 | 2017 |
| Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome S Colla, DST Ong, Y Ogoti, M Marchesini, NA Mistry, K Clise-Dwyer, ... Cancer cell 27 (5), 644-657, 2015 | 115 | 2015 |
| Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer P Pettazzoni, A Viale, P Shah, A Carugo, H Ying, H Wang, G Genovese, ... Cancer research 75 (6), 1091-1101, 2015 | 89 | 2015 |
| Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia E Follini, M Marchesini, G Roti International journal of molecular sciences 20 (12), 3021, 2019 | 73 | 2019 |
| PAF promotes stemness and radioresistance of glioma stem cells DST Ong, B Hu, YW Ho, CEG Sauvé, CA Bristow, Q Wang, AS Multani, ... Proceedings of the National Academy of Sciences 114 (43), E9086-E9095, 2017 | 52 | 2017 |
| Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy I Ganan-Gomez, H Yang, F Ma, G Montalban-Bravo, N Thongon, ... Nature medicine 28 (3), 557-567, 2022 | 45 | 2022 |
| Targeting oncogenic Notch signaling with SERCA inhibitors L Pagliaro, M Marchesini, G Roti Journal of Hematology & Oncology 14, 1-17, 2021 | 45 | 2021 |
| Blockade of oncogenic NOTCH1 with the SERCA inhibitor CAD204520 in T cell acute lymphoblastic leukemia M Marchesini, A Gherli, A Montanaro, L Patrizi, C Sorrentino, L Pagliaro, ... Cell chemical biology 27 (6), 678-697. e13, 2020 | 33 | 2020 |
| PML is required for telomere stability in non-neoplastic human cells M Marchesini, R Matocci, L Tasselli, V Cambiaghi, A Orleth, L Furia, ... Oncogene 35 (14), 1811-1821, 2016 | 32 | 2016 |
| Hematopoiesis under telomere attrition at the single-cell resolution N Thongon, F Ma, A Santoni, M Marchesini, E Fiorini, A Rose, V Adema, ... Nature communications 12 (1), 6850, 2021 | 22 | 2021 |
| Down-regulation of EZH2 expression in myelodysplastic syndromes M Cabrero, Y Wei, H Yang, I Ganan-Gomez, Z Bohannan, S Colla, ... Leukemia research 44, 1-7, 2016 | 20 | 2016 |
| Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia A Montanaro, S Kitara, E Cerretani, M Marchesini, C Rompietti, L Pagliaro, ... Cell Death & Disease 13 (6), 551, 2022 | 9 | 2022 |
| RNA processing: a new player of genomic instability in multiple myeloma M Marchesini, E Fiorini, S Colla Oncoscience 4 (7-8), 73, 2017 | 3 | 2017 |
| The role of Chip-related DNA damage response dysfunction in therapy-related myeloid neoplasms AA Pierola, M Marchesini, K Takahashi, I Gañán-Gómez, E Fiorini, Y Ogoti, ... Blood 128 (22), 958, 2016 | 2 | 2016 |
| A pool of peptides extracted from wheat bud chromatin inhibits tumor cell growth by causing defective DNA synthesis L Mancinelli, T Secca, PM De Angelis, F Mancini, M Marchesini, ... Cell Division 8, 1-10, 2013 | 2 | 2013 |
| Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: Switching from doublet to triplet. C Cerchione, D Nappi, L Catalano, S Ronconi, D Cangini, M Ceccolini, ... Journal of Clinical Oncology 40 (16_suppl), e20002-e20002, 2022 | 1 | 2022 |
| Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone C Cerchione, L Catalano, D Nappi, AE Pareto, G Musuraca, A Lucchesi, ... Blood 136, 18, 2020 | 1 | 2020 |
| Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520 M Marchesini, A Gherli, A Montanaro, S Kitara, C Sorrentino, L Pagliaro, ... Blood 134, 407, 2019 | 1 | 2019 |
| Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes I Gañán-Gómez, A Alfonso, Y Ogoti, H Yang, G Montalban-Bravo, ... Blood 128 (22), 4310, 2016 | 1 | 2016 |
